Improved survival after allogeneic transplantation for acute lymphoblastic leukemia in adults: a Danish population-based study

References

• Pulte D, Gondos A, Brenner H. Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood. 2009;113(7):1408–1411.
   PubMed Web of Science ®Google Scholar
• Ram R, Wolach O, Vidal L, et al. Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: systematic review and Meta-analysis. Am J Hematol. 2012;87(5):472–478.
   PubMed Web of Science ®Google Scholar
• Dinmohamed AG, Szabó A, van der Mark M, et al. Improved survival in adult patients with acute lymphoblastic leukemia in The Netherlands: a population-based study on treatment, trial participation and survival. Leukemia. 2016;30(2):310–317.
   PubMed Web of Science ®Google Scholar
• Toft N, Birgens H, Abrahamsson J, et al. Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. Leukemia. 2018;32(3):606–615.
   PubMed Web of Science ®Google Scholar
• Kansagra A, Dahiya S, Litzow M. Continuing challenges and current issues in acute lymphoblastic leukemia. Leuk Lymphoma. 2018;59(3):526–541.
   PubMed Web of Science ®Google Scholar
• Giebel S, Marks DI, Boissel N, et al. Hematopoietic stem cell transplantation for adults with philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the european working group for adult acute lymphoblastic leukemia (EWALL) and the acute leukemia working party of the european society for blood and marrow transplantation (EBMT). Bone Marrow Transplant. 2019;54(6):798–809.
   PubMed Web of Science ®Google Scholar
• Issa GC, Kantarjian HM, Yin CC, et al. Prognostic impact of pretreatment cytogenetics in adult philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer. 2017;123(3):459–467.
   PubMed Web of Science ®Google Scholar
• Short NJ, Jabbour E, Albitar M, et al. Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: a consensus of North american experts. Am J Hematol. 2019;94(2):257–265.
   PubMed Web of Science ®Google Scholar
• Hoelzer D, ESMO Guidelines Committee, Bassan R, Dombret H, et al. Acute lymphoblastic leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v69–v82.
   PubMed Web of Science ®Google Scholar
• Carobolante F, Chiaretti S, Skert C, et al. Practical guidance for the management of acute lymphoblastic leukemia in the adolescent and young adult population. Ther Adv Hematol. 2020;11:2040620720903531.
   Web of Science ®Google Scholar
• Sasaki K, Kantarjian HM, Short NJ, et al. Prognostic factors for progression in patients with philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer. 2021;127(15):2648–2656.
   PubMed Web of Science ®Google Scholar
• Copelan EA, Chojecki A, Lazarus HM, et al. Allogeneic hematopoietic cell transplantation; the current renaissance. Blood Rev. 2019;34:34–44.
   PubMed Web of Science ®Google Scholar
• Ribera JM, Morgades M, Ciudad J, et al. Chemotherapy or allogeneic transplantation in high-risk philadelphia chromosome-negative adult lymphoblastic leukemia. Blood. 2021;137(14):1879–1894.
   PubMed Web of Science ®Google Scholar
• Greil C, Engelhardt M, Ihorst G, et al. Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia. Bone Marrow Transplant. 2021;56(4):841–852.
   PubMed Web of Science ®Google Scholar
• Aladag E, Aktimur SH, Aydin O, et al. Allogeneic hematopoietic stem-cell transplantation improves Disease-Free survival compared to Pediatric-Inspired Berlin-Frankfurt-Munster chemotherapy in adult acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2021;21(3):147–153.
   PubMed Web of Science ®Google Scholar
• Lazaryan A, Acute Leukemia Committee of the CIBMTR, Dolan M, Zhang MJ, et al. Impact of cytogenetic abnormalities on outcomes of adult philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the acute leukemia working committee of the center for international blood and marrow transplant research. Haematologica. 2020;105(5):1329–1338.
   PubMed Web of Science ®Google Scholar
• Abdel Rahman ZH, Heckman MG, Miller K, et al. Impact of novel targeted therapies and cytogenetic risk groups on outcome after allogeneic transplantation for adult ALL. Transplant Cell Ther. 2021;27(2):165 e1–165 e11.
   Google Scholar
• Wieduwilt MJ, Stock W, Advani A, et al. Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. Leukemia. 2021;35(7):2140–2140.
   PubMed Web of Science ®Google Scholar
• Yoon JH, Min GJ, Park SS, et al. Impact of donor type on long-term graft-versus-host disease-free/relapse-free survival for adult acute lymphoblastic leukemia in first remission. Bone Marrow Transplant. 2021;56(4):828–840.
   PubMed Web of Science ®Google Scholar
• Webster JA, Luznik L, Tsai HL, et al. Allogeneic transplantation for Ph + acute lymphoblastic leukemia with posttransplantation cyclophosphamide. Blood Adv. 2020;4(20):5078–5088.
   PubMed Web of Science ®Google Scholar
• Giebel S, Labopin M, Socié G, et al. Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the acute leukemia working party of the european society for blood and marrow transplantation. Haematologica. 2017;102(1):139–149.
   PubMed Web of Science ®Google Scholar
• Østgård LS, Nørgaard JM, Raaschou-Jensen KK, et al. The danish national acute leukemia registry. Clin Epidemiol. 2016;8:553–560.
   PubMed Web of Science ®Google Scholar
• Gjaerde LI, Moser C, Sengelov H. Epidemiology of bloodstream infections after myeloablative and non-myeloablative allogeneic hematopoietic stem cell transplantation: a single-center cohort study. Transpl Infect Dis. 2017;19(5):e12730.
   Web of Science ®Google Scholar
• van der Velden VH, Hochhaus A, Cazzaniga G, et al. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia. 2003;17(6):1013–1034.
   PubMed Web of Science ®Google Scholar
• van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia. 2003;17(12):2257–2317.
   PubMed Web of Science ®Google Scholar
• Modvig S, Hallbook H, Madsen HO, et al. Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting. Leukemia. 2021;35(7):1894–1906.
   PubMed Web of Science ®Google Scholar
• Modvig S, Madsen HO, Siitonen SM, et al. Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia. Leukemia. 2019;33(6):1324–1336.
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825–828.
   PubMed Web of Science ®Google Scholar
• Royston P, Parmar MK. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med. 2002;21(15):2175–2197.
   PubMed Web of Science ®Google Scholar
• Othus M, Barlogie B, Leblanc ML, et al. Cure models as a useful statistical tool for analyzing survival. Clin Cancer Res. 2012;18(14):3731–3736.
   PubMed Web of Science ®Google Scholar
• Lambert PC. Modeling of the cure fraction in survival studies. The Stata Journal. 2007;7(3):351–375.
   Web of Science ®Google Scholar
• Jakobsen LH. cuRe: Parametric Cure Model Estimation. https://CRAN.R-project.org/package=cuRe
   Google Scholar
• University of California Berkeley, USA, Max Planck Institute for Demographic Research, Germany. Human Mortality Database. 2021. www.mortality.org
   Google Scholar
• Rohrer JM. Thinking clearly about correlations and causation: Graphical causal models for observational data. Adv Methods Prac Psychol Sci. 2018;1(1):27–42.
   Google Scholar
• Phelan R, Arora M, Chen M. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides. 2020. www.cibmtr.org/ReferenceCenter/SlidesReports/SummarySlides/
   Google Scholar
• Aldoss I, Tsai NC, Slovak ML, et al. Cytogenetics does not impact outcomes in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22(7):1212–1217.
   PubMed Web of Science ®Google Scholar
• Laport GG, Alvarnas JC, Palmer JM, et al. Long-term remission of philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen. Blood. 2008;112(3):903–909.
   PubMed Web of Science ®Google Scholar
• The Danish National Acute Leukemia Registry. Årsrapport 2019. [Danish]. https://leukemia.hematology.dk/index.php/om-alg/arsrapporter/403-alg-arsrapport-2019/file
   Google Scholar
• Bishop MR, Logan BR, Gandham S, et al. Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the national marrow donor program and center for international blood and marrow transplant research. Bone Marrow Transplant. 2008;41(7):635–642.
   PubMed Web of Science ®Google Scholar
• Pavlů J, Labopin M, Niittyvuopio R, et al. Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT. J Hematol Oncol. 2019;12(1):108.
   PubMed Web of Science ®Google Scholar
• Spinelli O, Peruta B, Tosi M, et al. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica. 2007;92(5):612–618.
   PubMed Web of Science ®Google Scholar
• Lussana F, Intermesoli T, Gianni F, et al. Achieving molecular remission before allogeneic stem cell transplantation in adult patients with philadelphia Chromosome-Positive acute lymphoblastic leukemia: Impact on relapse and long-term outcome. Biol Blood Marrow Transplant. 2016;22(11):1983–1987.
   PubMed Web of Science ®Google Scholar
• Warraich Z, Tenneti P, Thai T, et al. Relapse prevention with tyrosine kinase inhibitors after allogeneic transplantation for philadelphia chromosome-positive acute lymphoblast leukemia: a systematic review. Biol Blood Marrow Transplant. 2020;26(3):e55–e64.
   PubMedGoogle Scholar